An international working group led by England’s health technology assessment (HTA) agency NICE has produced best practice guidance for drugmakers on how to select surrogate endpoints and check that these are suitable for evidence submissions in the context of cost-effectiveness.
In addition to NICE, the working group included Canada’s drug and health technologies agency (CDA-AMC), the US Institute for Clinical...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?